Sands BE, D'Haens G, Clemow DB, Irving PM, et al. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflamm Bowel Dis 2024 Mar 9:izae024. doi: 10.1093.
PMID: 38459910